Corbus Pharmaceuticals Holdings Management
Management criteria checks 4/4
Corbus Pharmaceuticals Holdings' CEO is Yuval Cohen, appointed in Apr 2014, has a tenure of 10.08 years. total yearly compensation is $1.14M, comprised of 52.6% salary and 47.4% bonuses, including company stock and options. directly owns 0.099% of the company’s shares, worth $389.36K. The average tenure of the management team and the board of directors is 6.4 years and 5.5 years respectively.
Key information
Yuval Cohen
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | 52.6% |
| CEO tenure | 10.1yrs |
| CEO ownership | 0.1% |
| Management average tenure | 6.4yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug
Jan 30Corbus Pharmaceuticals GAAP EPS of -$0.11
Aug 09Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Using Too Much Debt?
Nov 19
Here's Why Shareholders Should Examine Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package More Closely
Jun 12Should Shareholders Reconsider Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package?
May 14What Kind Of Shareholders Hold The Majority In Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Shares?
Mar 11Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?
Feb 04Corbus Pharmaceuticals: Down But Not Out
Jan 29Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year?
Jan 09Corbus's lenabasum shows benefit in autoimmune disorder
Nov 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$1m | US$599k | -US$45m |
| Sep 30 2023 | n/a | n/a | -US$47m |
| Jun 30 2023 | n/a | n/a | -US$46m |
| Mar 31 2023 | n/a | n/a | -US$51m |
| Dec 31 2022 | US$1m | US$598k | -US$42m |
| Sep 30 2022 | n/a | n/a | -US$42m |
| Jun 30 2022 | n/a | n/a | -US$35m |
| Mar 31 2022 | n/a | n/a | -US$39m |
| Dec 31 2021 | US$5m | US$579k | -US$46m |
| Sep 30 2021 | n/a | n/a | -US$44m |
| Jun 30 2021 | n/a | n/a | -US$77m |
| Mar 31 2021 | n/a | n/a | -US$98m |
| Dec 31 2020 | US$3m | US$559k | -US$111m |
| Sep 30 2020 | n/a | n/a | -US$129m |
| Jun 30 2020 | n/a | n/a | -US$115m |
| Mar 31 2020 | n/a | n/a | -US$75m |
| Dec 31 2019 | US$4m | US$559k | -US$71m |
| Sep 30 2019 | n/a | n/a | -US$62m |
| Jun 30 2019 | n/a | n/a | -US$56m |
| Mar 31 2019 | n/a | n/a | -US$70m |
| Dec 31 2018 | US$4m | US$540k | -US$56m |
| Sep 30 2018 | n/a | n/a | -US$49m |
| Jun 30 2018 | n/a | n/a | -US$41m |
| Mar 31 2018 | n/a | n/a | -US$37m |
| Dec 31 2017 | US$3m | US$463k | -US$32m |
Compensation vs Market: Yuval's total compensation ($USD1.14M) is below average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Yuval's compensation has been consistent with company performance over the past year.
CEO
Yuval Cohen (48 yo)
10.1yrs
Tenure
US$1,137,622
Compensation
Dr. Yuval Cohen, Ph.D. has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 10.1yrs | US$1.14m | 0.099% $ 389.4k | |
| Chief Financial Officer | 10.1yrs | US$717.26k | 0.080% $ 314.0k | |
| Head of Corporate Communications & Patient Advocacy | no data | no data | no data | |
| Head of Human Resources | 2.8yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
6.4yrs
Average Tenure
48yo
Average Age
Experienced Management: CRBP's management team is seasoned and experienced (6.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 10.1yrs | US$1.14m | 0.099% $ 389.4k | |
| Independent Director | 9.8yrs | US$111.91k | 0.015% $ 58.4k | |
| Independent Chairman | 10.3yrs | US$120.66k | 0.013% $ 51.4k | |
| Independent Director | 1.7yrs | US$30.83k | 0% $ 0 | |
| Independent Director | 5.9yrs | US$109.74k | 0.00031% $ 1.2k | |
| Independent Director | 1.2yrs | US$94.21k | 0% $ 0 | |
| Independent Director | 5.1yrs | US$104.42k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$66.27k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data |
5.5yrs
Average Tenure
56.5yo
Average Age
Experienced Board: CRBP's board of directors are considered experienced (5.5 years average tenure).